Log in

NASDAQ:ARRY - Array Biopharma Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$47.85
0.00 (0.00 %)
(As of 12/10/2019 04:58 AM ET)
Today's Range
$47.85
Now: $47.85
$47.85
50-Day Range
$47.85
MA: $47.85
$47.85
52-Week Range
$12.56
Now: $47.85
$47.98
VolumeN/A
Average Volume4.99 million shs
Market Capitalization$10.68 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.7
Array BioPharma Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer and other diseases in North America, Europe, and the Asia Pacific. It provides BRAFTOVITM (encorafenib) capsules in combination with MEKTOVI (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF mutation. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ARRY
CUSIP04269X10
Phone303-381-6600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$173.77 million
Book Value$1.04 per share

Profitability

Net Income$-147,340,000.00

Miscellaneous

Employees298
Market Cap$10.68 billion
Next Earnings Date2/3/2020 (Estimated)
OptionableOptionable

Receive ARRY News and Ratings via Email

Sign-up to receive the latest news and ratings for ARRY and its competitors with MarketBeat's FREE daily newsletter.


Array Biopharma (NASDAQ:ARRY) Frequently Asked Questions

What is Array Biopharma's stock symbol?

Array Biopharma trades on the NASDAQ under the ticker symbol "ARRY."

How were Array Biopharma's earnings last quarter?

Array Biopharma Inc (NASDAQ:ARRY) released its quarterly earnings results on Tuesday, October, 30th. The biopharmaceutical company reported ($0.12) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.22) by $0.10. The biopharmaceutical company had revenue of $56.91 million for the quarter, compared to analysts' expectations of $34.47 million. Array Biopharma had a negative net margin of 52.64% and a negative return on equity of 48.51%. Array Biopharma's revenue was up 91.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.22) earnings per share. View Array Biopharma's Earnings History.

When is Array Biopharma's next earnings date?

Array Biopharma is scheduled to release their next quarterly earnings announcement on Monday, February 3rd 2020. View Earnings Estimates for Array Biopharma.

What price target have analysts set for ARRY?

11 brokerages have issued twelve-month price targets for Array Biopharma's stock. Their forecasts range from $25.00 to $48.00. On average, they expect Array Biopharma's share price to reach $38.47 in the next twelve months. This suggests that the stock has a possible downside of 19.6%. View Analyst Price Targets for Array Biopharma.

What is the consensus analysts' recommendation for Array Biopharma?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Array Biopharma in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Array Biopharma.

Has Array Biopharma been receiving favorable news coverage?

Press coverage about ARRY stock has trended somewhat negative on Tuesday, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Array Biopharma earned a daily sentiment score of -1.2 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Array Biopharma.

Who are some of Array Biopharma's key competitors?

What other stocks do shareholders of Array Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Array Biopharma investors own include Puma Biotechnology (PBYI), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Continental (UAL), Exelixis (EXEL), Kite Pharma (KITE) and Omeros (OMER).

Who are Array Biopharma's key executives?

Array Biopharma's management team includes the folowing people:
  • Mr. Ron Squarer, CEO & Director (Age 52)
  • Mr. Jason Haddock, Chief Financial Officer (Age 49)
  • Mr. Andrew R. Robbins, Chief Operating Officer (Age 43)
  • Dr. Victor Sandor, Chief Medical Officer (Age 53)
  • Dr. Nicholas A. Saccomano, Chief Scientific Officer (Age 60)

What is Array Biopharma's stock price today?

One share of ARRY stock can currently be purchased for approximately $47.85.

How big of a company is Array Biopharma?

Array Biopharma has a market capitalization of $10.68 billion and generates $173.77 million in revenue each year. The biopharmaceutical company earns $-147,340,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis. Array Biopharma employs 298 workers across the globe.View Additional Information About Array Biopharma.

What is Array Biopharma's official website?

The official website for Array Biopharma is http://www.arraybiopharma.com/.

How can I contact Array Biopharma?

Array Biopharma's mailing address is 3200 Walnut Street, Boulder CO, 80301. The biopharmaceutical company can be reached via phone at 303-381-6600 or via email at [email protected]


MarketBeat Community Rating for Array Biopharma (NASDAQ ARRY)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  485 (Thanks for Voting!)
Underperform Votes:  310 (Thanks for Voting!)
Total Votes:  795
MarketBeat's community ratings are surveys of what our community members think about Array Biopharma and other stocks. Vote "Outperform" if you believe ARRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARRY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel